In all the ongoing developments of COVID-19 infection, many health facilities have attracted a lot of attention during this crisis. At the same time, several promising companies have gone under the radar and boosted their stocks.
This is especially true for small biotech stocks not involved in developing tests, vaccines, or treatments for COVID-19. Immunization manufacturers, drug manufacturers, and health professionals draw a lot of attention during this disease, but there are many promising resources for biotechnology that are not involved in this field. . Here are two companies you may have missed, but they should be added to your checklist.
1. Trillium Treatment
Trillium Therapeutics (NASDAQ: TRIL) is a small-cap biotechnology product whose price has increased significantly so far in 2020. Trading penny products in 2019, Trillium has nearly quadrupled in price since its inception. . ‘ many years. Given that climate change has caused COVID-19 to thrive around the world, it’s no surprise that this industry report will make you happy.
Trillium is one of the few companies to develop CD47-based treatments, the area is now one of the most popular areas for cancer diagnosis. Simply put, CD47 is a protein found on top of cells that prompts immune cells (types of white blood cells such as T lymphocytes) to leave these cells alone. However, it occurs in almost all types of cancer cells filled with CD47 protein, which explains why the immune system is difficult to focus on these cells first. By blocking this CD47 protein, the immune system can target and kill cancer cells just like any other malignant cell in the body.
Currently, Trillium has two people based on CD47 and clinical trials. TTI-621 tries to treat many blood cancers, including B and T-cell lymphoma, and TTI-622 is followed by myeloma, a type of cancer that develops in plasma cells. Both candidates are currently in Phase 1 testing, and while they are still promising, there is still a long way to go before the company is ready to apply for legal approval.
What makes many experts happy about Trillium, however, is its ability as a goal to achieve. Gilead Science announced plans to buy $4.9 billion in March for the CD47-based treatment, magnolia. With such a small number of CD47 producers out there, there is a lot of speculation about Trillium as well as whether it will be the next target for pharmaceutical manufacturers. If so, Trillium shareholders have a lot to gain by holding shares now.
Additionally, Trillium is expected to deliver several clinical updates in 2020. These include a mid-year update and presentation at the American Society of Clinical Oncology (ASCO) cancer conference expected in late May. While Trillium doesn’t have a huge investment right now – which is understandable since it’s the start of a biotechnology product – the company has a huge amount of money to spend in real-time. Trillium currently has $130 million in revenue, and with a 2019 total value of $38.8 million, the company has more than three years of cash flow opportunities.
If Trillium isn’t on your product list, you should keep an eye on it in the coming months. Between hospital updates and other shopping deals, there’s a lot to enjoy in this industry.
2. BioDelivery Sciences
While the issue of opioids and their decline remains a major problem for Americans, it is a question of abandonment due to the COVID-19 disease. It’s a shame that many biotech companies aren’t making great strides in pain management, but aren’t getting the attention they deserve.
BioDelivery Sciences (NASDAQ: BDSI) is one of them. With a market capitalization of approximately $ 400 million, the share of these biotech products has decreased by about a third since the beginning of 2020. In contrast, the net sales of Biomedical Sciences are higher than ever. growing.
The company focuses on developing therapies that help patients manage chronic pain. Conventional opioids are short-lived, between four and six hours, depending on the particular drug. Patients often have to take several doses per day, which is considered a risk factor for a drug overdose.
BioDelivery’s flagship pain reliever, Belbuca, is a specific type of opioid known as buprenorphine that is being marketed as a potential substitute for conventional opioids. The idea is that long-acting opioids that require small doses and prevent early hospitalization have a lower risk of overdose.
In medical science, the use of buprenorphine is nothing new. They have been effective in treating opioid-addicted patients, helping them eliminate difficult opioids and reduce relapses. Additionally, buprenorphine is safer than regular opioids in certain medical conditions, such as patients with impaired kidney or liver function who still need pain relief.
Belbuca is seen directly on other buprenorphine because it is the only drug used to dissolve and enter the mouth. The drug received initial approval from the Food and Drug Administration (FDA) in 2015 following the results of 3 studies involving patients with chronic back pain.
Looking at BioDelivery’s results for the fourth quarter of 2019, the demand for Belbuca looks strong. Network sales were $ 31.6 million, up 75% from the fourth quarter of 2018. This is roughly the same for Belbuca, which generated $ 28.3 million in revenue for the quarter. . While the company still reports that it costs around $ 15.3 million for the full year, BioDelivery could make a profit in 2020 if growth continues to grow, as it appears, and millions of Americans might consider it another haven is Belbuca. traditional opioids.